HUGRPHA@EC2601A

Furay Medicine Submits New Drug Application for TLX591-CDx to China's NMPA

Huadaxiyao's Radiopharmaceutical TLX250-CDx Clinical Trial Results Published

Farmiton Medical Multiple Innovative Products Show Promising Clinical Progress

Farasis Medical Acquires Hebei Yunda Jiufu Biotechnology Co., Ltd. to Strengthen Amino Acid Industrial Chain Layout

Yuanda Pharmaceutical Makes Breakthroughs in Nuclear Medicine Oncology

Farapulse Secures Commercialization Rights for Neffy® in Mainland China

Farmito Obtains Exclusive Commercialization Rights for Neffy® in Mainland China

Yongan Pharmaceutical's TLX591-CDx Phase III Clinical Trial Reaches Primary Endpoint

Fujian Grand Pharmaceutical's Radioactive Drug Approved by FDA for Clinical Trials

Guoyuan International Upgrades Views on Far East Medical’s Innovative Drug R&D, Raises Target Price

Farmiton’s Antidepressant Drug GPN01360 Successfully Completes Phase II Clinical Trials in China

Farmito Pharmaceutical Obtains Ryaltris Market Approval in China

Huaxi Securities Upgrades Yuanda Medicine to 'Buy' Rating for the First Time

YuanDa Pharmaceutical Launches Varenicline Tartrate Nasal Spray, A New Approach to Treating Dry Eye Syndrome

Farapulse OC-01 Dry Eye Treatment Drug Launches Nationwide

Farapulse Completes First Patient Enrollment in IIa Phase Clinical Trial for GPN00884 Eye Drops in China

Tang Weikun Increases Holdings in Far Eastern Horizon

Farasis Medical's Global Innovative Artificial Vessel aXess Achieves Success in Overseas Key Clinical Trials

YMD Global's Innovative Embolic Agent GPN00289 Completes Registration Clinical Trial Patient Enrollment

UNI PRINTSHOP

WING CHI HLDGS

CINESE INTL

WAN KEI GROUP

CHINA WACAN

JH EDUCATION

DIGITAL DOMAIN

LOTUS HORIZON

VICO INTL HLDGS

K W NELSON GP

00512

000963

Grand Pharmaceutical Group Ltd. has announced the full acquisition of Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for a purchase price of 316 million RMB. This price was determined after negotiations and based on an independent assessment valuing the target companies at approximately 324 million RMB as of September 30, 2025. The announcement includes details on the valuation methodology, particularly the use of the Enterprise-Value-to-Sales multiple to reflect recent business performance and capital structure.

Reuters

Yinhua CSI Innovative Drugs Industry ETF

GRANDPHARMA

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

捍宇医疗

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Hwabao WP CSI Pharmaceuticals ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

GRAND HOLDING

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI Biotechnology Theme ETF

HUADONG MEDICINE

Minsheng Royal CSI Biotechnology Theme ETF

Grand Pharmaceutical Group kündigt Übernahme von Hebei Yuanda Jiufu Biotechnology und Baoding Jiahe Fine Chemical an

On January 12th, GRANDPHARMA (0512.HK) fluctuated around the HKD 8 level throughout the day, with the pharmaceutical sector recently becoming a heavy area of capital outflow, and the market continues to be under pressure. The company has no new product applications or favorable external mergers and acquisitions, resulting in a short-term "vacuum period." There were occasional surges during the trading session, but they were ultimately suppressed by short sellers, and the weak rebound could not break the pressure pattern. MACD, KDJ, and Bollinger Bands are all weakening, with a strong atmosphere of bottoming out in a sideways trend. Pharmaceutical policy regulation is tightening, and there are no significant new drugs or restructuring stimuli in the market. Mainstream capital is actively avoiding risks, and the overall sentiment is calm. Analysts believe that only a shift to looser policies or the restart of major projects will ignite a recovery market. Sudden mergers/acquisitions or drug progress during trading could signal short-term speculation; otherwise, there is sufficient downward momentum. Risk control: Pay attention to the movements of industry leaders and policy news, with a defensive approach to operations. Extreme trends may lead to a new round of declines due to capital bleeding

Technical Forecast

Morning Trend | GRANDPHARMA tests new lows again, can the main line rebound from the pressure of negative factors in the sector?

GRANDPHARMA announced that its subsidiary Hubei GRANDPHARMA has signed a share purchase agreement to acquire 100% equity of Hebei GRANDPHARMA Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for RMB 316 million. These two companies focus on the production and sales of amino acids and thiol products. This acquisition will enhance the company's ability to integrate its industrial chain and promote its market expansion in the nutrition and daily chemical fields

AASTOCKS

GRANDPHARMA subsidiary spends 316 million RMB to acquire an amino acid product company

On December 17th, GRANDPHARMA (512.HK) continued to consolidate weakly, with low trading activity throughout the day and funds remaining cautious. The significant fluctuations during the session lacked strong participation from major players, the MACD death cross remains unresolved, and the moving average system is entirely bearish. The short-term market relies on support at the 5.06 yuan level. There is a scarcity of excitement in the industry sector, with slow progress in new drug approvals and policy changes. Although there were news about local access for innovative drugs this week, the details have not been finalized, and the enthusiasm for fund participation has not been ignited. The leading stocks in the sector continue to observe, and small-cap stocks see quick rises during the session followed by profit-taking. Key attention should be paid to the gains and losses of support levels and changes in intraday volume; a simultaneous rise in volume and price is a necessary condition for a rebound. The overall market lacks a leading trend, and short-term focus should be on unusual movements by major players and marginal policy events. If no substantial signals are observed, it is recommended that investors remain cautious, avoid chasing prices, and steer clear of the risk of secondary declines caused by breaking support

Morning Trend | GRANDPHARMA consolidates with reduced volume, can the key support hold?

GRANDPHARMA rose over 6% in the morning, and as of the time of writing, it has increased by 6.42%, trading at HKD 8.79, with a transaction volume of HKD 101 million. In terms of news, GRANDPHARMA recently announced that the global innovative ophthalmic drug GPN00884, used to delay the progression of myopia in children, has completed the enrollment and dosing of the first patient in its Phase IIa clinical study in China. This means that GPN00884 will enter an important phase to explore drug dosage and assess preliminary efficacy. If the expected drug effectiveness is successfully realized, clinical practice may welcome a new solution for alleviating the progression of myopia in children. It is worth noting that in July of this year, the oxymetazoline hydrochloride nasal spray (OC-01) was launched in mainland China, revolutionizing the treatment experience for dry eye patients through nasal spray. Recently, GRANDPHARMA successfully held a national launch conference for OC-01, taking advantage of the 11th Global Dry Eye Academic Conference themed "Caring for Dry Eye Patients, Welcoming the Era of Native Tears - 2025 New Advances in Dry Eye Diagnosis and Treatment and the Construction of Ocular Surface Health Ecology," officially announcing the arrival of a new era in dry eye treatment from "external replacement" to "internal awakening."

Zhitong

Understanding the Market | GRANDPHARMA rose over 6% in the morning as the new myopia drug GPN00884 recently started its Phase IIa clinical trial in China

GRANDPHARMA successfully held the national launch conference for OC-01 at the 11th Global Dry Eye Academic Conference, marking a new era in the treatment of dry eye disease. The OC-01 nasal spray innovates the treatment experience for dry eye patients by promoting the secretion of natural tears. This conference brought together multiple ophthalmology experts to discuss the current status and future of dry eye prevention and treatment, emphasizing the importance of eye health issues on the quality of life of the population

GRANDPHARMA leads a new era in dry eye treatment with the successful national launch of the world's first dry eye nasal spray OC-01

GRANDPHARMA announced that the first patient has been enrolled in the Phase IIa clinical study of its global innovative ophthalmic drug GPN00884 in China. The study aims to evaluate the efficacy and safety of GPN00884 eye drops in slowing the progression of myopia in children, with plans to recruit 80 myopic patients aged 6 to 12 years. GPN00884 has a new mechanism that avoids the side effects of low-concentration atropine, meeting the clinical needs for the treatment of myopia in children in China. This study marks an important advancement for the company in the field of ophthalmology

GRANDPHARMA: The Phase IIa clinical study of the global innovative ophthalmic drug GPN00884 has completed the enrollment of its first patient in China

According to the latest information from the Hong Kong Stock Exchange, on October 13th, Chairman Tang Weikun increased his holdings in GRANDPHARMA by 50,000 shares at a price of HKD 8.21 per share, totaling HKD 410,500. After the increase, the latest number of shares held is 950,000, with a latest holding ratio of 0.03%

Chairman Tang Weikun increased his holdings in GRANDPHARMA by 50,000 shares at a price of HKD 8.21 per share

GRANDPHARMA's globally innovative artificial blood vessel product aXess has achieved success in critical clinical trials, demonstrating safety and efficacy superior to current standard therapies. This breakthrough is expected to provide a safer and more effective hemodialysis treatment option for patients with end-stage renal disease (ESRD), marking an important milestone for GRANDPHARMA in the field of precision interventional diagnosis and treatment for cardiovascular and cerebrovascular diseases. It is estimated that by 2030, the number of ESRD patients worldwide will increase to nearly 14.61 million, with Chinese patients accounting for over 30%

GRANDPHARMA aXess demonstrates globally leading revolutionary potential, accelerating global innovation layout and advancing the "Go Global" strategy

GRANDPHARMA's global innovative artificial blood vessel aXess has achieved success in key overseas clinical trials, demonstrating its revolutionary potential in the field of hemodialysis treatment. This advancement marks an important breakthrough in the company's "Go Global" strategy, enhancing the competitiveness of its high-end medical devices and promising new treatment options for end-stage renal disease patients in the future. aXess utilizes endogenous tissue repair technology aimed at improving the establishment of vascular access and reducing the risk of complications

Aiming at the hundred billion dollar blue ocean market, GRANDPHARMA's innovative artificial blood vessels have made breakthrough progress in key overseas clinical trials. The "Go Global" strategy is steady and far-reaching

HUGRPHA@EC2601A(18251.HK)

Grand Pharmaceutical Group kündigt Übernahme von Hebei Yuanda Jiufu Biotechnology und Baoding Jiahe Fine Chemical an

Morning Trend | GRANDPHARMA tests new lows again, can the main line rebound from the pressure of negative factors in the sector?

GRANDPHARMA subsidiary spends 316 million RMB to acquire an amino acid product company

Morning Trend | GRANDPHARMA consolidates with reduced volume, can the key support hold?

Understanding the Market | GRANDPHARMA rose over 6% in the morning as the new myopia drug GPN00884 recently started its Phase IIa clinical trial in China